Verano Holdings (VRNO) Amortization of Deferred Charges (2021 - 2026)
Verano Holdings' (VRNO) quarterly Amortization of Deferred Charges came in at $3.0 million in Q1 2026, up 1.52% year-on-year from $3.0 million in Q1 2025, and little changed on a QoQ basis from $3.0 million in Q4 2025.
Verano Holdings (VRNO) Amortization of Deferred Charges (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has 6 years of Amortization of Deferred Charges data on file, last reported at $3.0 million in Q1 2026.
- On a quarterly basis, Amortization of Deferred Charges rose 1.52% year-over-year to $3.0 million in Q1 2026; TTM through Mar 2026 was $12.0 million, a 7.2% increase from a year earlier, with the FY2025 full-year figure at $12.0 million, up 7.1% from the prior year.
- Amortization of Deferred Charges for Q1 2026 stood at $3.0 million, roughly flat from $3.0 million in the prior quarter.
- Over the last five years, Amortization of Deferred Charges for VRNO reached as high as $3.9 million in Q2 2024 and fell as low as $1.5 million in Q1 2022.
- Historically, Amortization of Deferred Charges has averaged $2.7 million across 5 years, with a median of $2.7 million in 2023.
- Across the five-year window, Amortization of Deferred Charges soared 167.88% in 2022 and sank 34.9% in 2024, its largest moves.
- Year by year, Amortization of Deferred Charges stood at $2.5 million in 2022, then grew by 7.64% to $2.7 million in 2023, then sank by 34.9% to $1.7 million in 2024, then jumped by 74.5% to $3.0 million in 2025, then fell by 0.46% to $3.0 million in 2026.
- Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $3.0 million in Q1 2026, $3.0 million in Q4 2025, and $3.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Verano Holdings | 2.02 Bn | 1.94 Bn | 98.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.01 Mn |
| Mar 31, 2026 | 3.01 Mn |
| Dec 31, 2025 | 3.02 Mn |
| Dec 31, 2025 | 3.02 Mn |
| Sep 30, 2025 | 3.00 Mn |
| Sep 30, 2025 | 3.00 Mn |
| Jun 30, 2025 | 3.01 Mn |
| Jun 30, 2025 | 3.01 Mn |
| Mar 31, 2025 | 2.97 Mn |
| Mar 31, 2025 | 2.97 Mn |
| Dec 31, 2024 | 1.73 Mn |
| Dec 31, 2024 | 1.73 Mn |
| Sep 30, 2024 | 2.65 Mn |
| Sep 30, 2024 | 2.65 Mn |
| Jun 30, 2024 | 3.88 Mn |
| Jun 30, 2024 | 3.88 Mn |
| Mar 31, 2024 | 2.93 Mn |
| Mar 31, 2024 | 2.93 Mn |
| Dec 31, 2023 | 2.66 Mn |
| Dec 31, 2023 | 2.66 Mn |